RU94042386A - Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита - Google Patents

Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита

Info

Publication number
RU94042386A
RU94042386A RU94042386/14A RU94042386A RU94042386A RU 94042386 A RU94042386 A RU 94042386A RU 94042386/14 A RU94042386/14 A RU 94042386/14A RU 94042386 A RU94042386 A RU 94042386A RU 94042386 A RU94042386 A RU 94042386A
Authority
RU
Russia
Prior art keywords
hepatitis
treatment
lipid
preparation
antigen
Prior art date
Application number
RU94042386/14A
Other languages
English (en)
Other versions
RU2121849C1 (ru
Inventor
Мария-Жозеф Клод Гаркон-Джонсон Натали
Fr]
Озер Пьер
Тирьяр Клотильда
Be]
Вет Пьер
Original Assignee
Смитклайн Бичам Байолоджикалс С.А. (Be)
Смитклайн Бичам Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27450853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU94042386(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929206789A external-priority patent/GB9206789D0/en
Priority claimed from GB929206788A external-priority patent/GB9206788D0/en
Priority claimed from GB929206797A external-priority patent/GB9206797D0/en
Priority claimed from GB929206786A external-priority patent/GB9206786D0/en
Application filed by Смитклайн Бичам Байолоджикалс С.А. (Be), Смитклайн Бичам Байолоджикалс С.А. filed Critical Смитклайн Бичам Байолоджикалс С.А. (Be)
Publication of RU94042386A publication Critical patent/RU94042386A/ru
Application granted granted Critical
Publication of RU2121849C1 publication Critical patent/RU2121849C1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Предложен вакцинный препарат для лечения или профилактики инфекции гепатита, особенно гепатита B, состоящий из антигена гепатита и приемлемого носителя, например алюмината с 3-0-дезацилированным монофосфорил-липидом A. Описаны также комбинированные вакцины, включающие указанный вакцинный препарат

Claims (1)

  1. Предложен вакцинный препарат для лечения или профилактики инфекции гепатита, особенно гепатита B, состоящий из антигена гепатита и приемлемого носителя, например алюмината с 3-0-дезацилированным монофосфорил-липидом A. Описаны также комбинированные вакцины, включающие указанный вакцинный препарат.
RU94042386A 1992-03-27 1993-03-24 Вакцинная композиция против гепатита, способ профилактики гепатита RU2121849C1 (ru)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB9206789.1 1992-03-27
GB929206789A GB9206789D0 (en) 1992-03-27 1992-03-27 Vaccine
GB9206786.7 1992-03-27
GB9206788.3 1992-03-27
GB929206788A GB9206788D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206797A GB9206797D0 (en) 1992-03-27 1992-03-27 Vaccine
GB929206786A GB9206786D0 (en) 1992-03-27 1992-03-27 Vaccine
GB9206797.4 1992-03-27

Publications (2)

Publication Number Publication Date
RU94042386A true RU94042386A (ru) 1996-08-20
RU2121849C1 RU2121849C1 (ru) 1998-11-20

Family

ID=27450853

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94042386A RU2121849C1 (ru) 1992-03-27 1993-03-24 Вакцинная композиция против гепатита, способ профилактики гепатита

Country Status (28)

Country Link
EP (1) EP0633784B2 (ru)
JP (1) JP3470719B2 (ru)
KR (1) KR100270134B1 (ru)
CN (1) CN1072963C (ru)
AP (1) AP570A (ru)
AT (1) ATE146678T1 (ru)
AU (4) AU3751693A (ru)
CA (1) CA2132833C (ru)
CZ (1) CZ283424B6 (ru)
DE (1) DE69306940T3 (ru)
DK (1) DK0633784T4 (ru)
ES (1) ES2098029T5 (ru)
FI (1) FI110843B (ru)
GR (1) GR3022174T3 (ru)
HK (1) HK1003218A1 (ru)
HU (1) HU221253B1 (ru)
IL (1) IL105161A (ru)
MA (1) MA22842A1 (ru)
MY (1) MY111880A (ru)
NO (1) NO309458B1 (ru)
NZ (1) NZ249868A (ru)
RU (1) RU2121849C1 (ru)
SA (1) SA93130573B1 (ru)
SG (1) SG48375A1 (ru)
SI (1) SI9300149B (ru)
SK (1) SK280160B6 (ru)
UA (1) UA44688C2 (ru)
WO (1) WO1993019780A1 (ru)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
ES2162139T5 (es) * 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6488934B1 (en) 1995-02-25 2002-12-03 Smithkline Beecham Biologicals S.A. Hepatitis B vaccine
GB9513261D0 (en) * 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
IL137998A0 (en) * 1998-03-09 2001-10-31 Smithkline Beecham Biolog Combined vaccine compositions
US6306404B1 (en) 1998-07-14 2001-10-23 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid A
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
GB9822714D0 (en) * 1998-10-16 1998-12-09 Smithkline Beecham Sa Vaccines
FI108150B (fi) 1999-02-15 2001-11-30 Sulzer Pumpen Ag Menetelmä ja laitteisto massan käsittelemiseksi
US6635261B2 (en) 1999-07-13 2003-10-21 Wyeth Holdings Corporation Adjuvant and vaccine compositions containing monophosphoryl lipid A
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ES2540770T3 (es) 2004-09-22 2015-07-13 Glaxosmithkline Biologicals Sa Composición inmunógena para uso en vacunación contra estafilococos
TW200722101A (en) 2005-03-23 2007-06-16 Glaxosmithkline Biolog Sa Novel composition
PL2368572T3 (pl) 2005-11-04 2020-11-16 Seqirus UK Limited Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
JP2009514839A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
CA2628328A1 (en) 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics S.R.L. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ567978A (en) 2005-11-04 2011-09-30 Novartis Vaccines & Diagnostic Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
PT1962899E (pt) 2005-12-22 2011-10-19 Glaxosmithkline Biolog Sa Vacina conjugada polissacarídica pneumocócica
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3753574A1 (en) 2006-01-27 2020-12-23 Seqirus UK Limited Influenza vaccines containing hemagglutinin and matrix proteins
EP2010537B1 (en) 2006-03-23 2011-12-28 Novartis AG Imidazoquinoxaline compounds as immunomodulators
WO2007110776A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
EA020459B1 (ru) 2006-03-30 2014-11-28 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
MX2009000660A (es) 2006-07-17 2009-04-08 Glaxosmithkline Biolog Sa Vacuna de influenza.
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
NZ575271A (en) 2006-09-11 2011-09-30 Novartis Ag Making influenza virus vaccines without using eggs
PL2121011T3 (pl) 2006-12-06 2014-10-31 Novartis Ag Szczepionki zawierające antygeny czterech szczepów wirusa grypy
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
BRPI0813644B8 (pt) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina
CN101784283A (zh) 2007-06-27 2010-07-21 诺华有限公司 低添加流感疫苗
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009081172A1 (en) 2007-12-24 2009-07-02 Novartis Ag Assays for adsorbed influenza vaccines
AU2010220824A1 (en) 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
PL3178490T3 (pl) 2009-07-15 2022-08-01 Glaxosmithkline Biologicals S.A. Kompozycje białka f rsv i sposoby ich wytwarzania
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EA025152B1 (ru) 2010-12-02 2016-11-30 Бионор Иммуно Ас Конструкция пептидного каркаса
AU2012204955B2 (en) 2011-01-06 2016-10-06 Bionor Immuno As Monomeric and multimeric immunogenic peptides
EP4144368A1 (en) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
WO2012158613A1 (en) 2011-05-13 2012-11-22 Novartis Ag Pre-fusion rsv f antigens
KR20150018870A (ko) 2012-06-06 2015-02-24 바이오노르 이뮤노 에이에스 면역원 및 투여 반응제로서 사용하기 위한 바이러스 단백질로부터 유래하는 펩타이드
EP3313439A2 (en) 2015-06-26 2018-05-02 Seqirus UK Limited Antigenically matched influenza vaccines
US20230109142A1 (en) 2020-02-14 2023-04-06 Immunor As Corona virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
JPH02500880A (ja) * 1987-11-18 1990-03-29 カイロン　コーポレイション Ｎａｎｂｖの診断用薬およびワクチン
AU3748489A (en) * 1988-06-17 1990-01-12 Genelabs Incorporated Enterically transmitted non-a/non-b hepatitis viral agent
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE159031T1 (de) * 1989-07-25 1997-10-15 Smithkline Biolog Antigene sowie verfahren zu deren herstellung
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
IL97985A0 (en) * 1990-05-07 1992-06-21 North American Vaccine Inc Improved vaccine compositions
EP0563091A1 (en) * 1990-12-20 1993-10-06 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccines based on hepatitis b surface antigen

Also Published As

Publication number Publication date
AU3397499A (en) 1999-08-19
GR3022174T3 (en) 1997-03-31
EP0633784B2 (en) 2001-10-17
SG48375A1 (en) 1998-04-17
KR100270134B1 (ko) 2000-10-16
SK115294A3 (en) 1995-06-07
AU6445796A (en) 1996-11-07
HK1003218A1 (en) 1998-10-16
ES2098029T5 (es) 2002-03-16
IL105161A0 (en) 1993-07-08
ES2098029T3 (es) 1997-04-16
CZ235594A3 (en) 1995-02-15
CZ283424B6 (cs) 1998-04-15
SI9300149A (en) 1993-12-31
EP0633784A1 (en) 1995-01-18
AP9300502A0 (en) 1993-04-30
NO943571D0 (no) 1994-09-26
CN1085805A (zh) 1994-04-27
DE69306940D1 (de) 1997-02-06
AU767755B2 (en) 2003-11-20
MY111880A (en) 2001-02-28
SK280160B6 (sk) 1999-09-10
AU1000802A (en) 2002-02-21
HUT69931A (en) 1995-09-28
CA2132833C (en) 2007-03-06
KR950700757A (ko) 1995-02-20
DK0633784T3 (da) 1997-01-20
JP3470719B2 (ja) 2003-11-25
WO1993019780A1 (en) 1993-10-14
CA2132833A1 (en) 1993-10-14
RU2121849C1 (ru) 1998-11-20
NZ249868A (en) 1997-03-24
FI944442A (fi) 1994-09-26
ATE146678T1 (de) 1997-01-15
AU3751693A (en) 1993-11-08
FI944442A0 (fi) 1994-09-26
DE69306940T2 (de) 1997-06-26
AP570A (en) 1996-11-29
MA22842A1 (fr) 1993-10-01
HU221253B1 (en) 2002-09-28
HU9402758D0 (en) 1994-12-28
DK0633784T4 (da) 2001-12-31
NO943571L (no) 1994-11-14
JPH07505372A (ja) 1995-06-15
IL105161A (en) 1998-08-16
SI9300149B (sl) 2003-02-28
EP0633784B1 (en) 1996-12-27
DE69306940T3 (de) 2002-09-19
NO309458B1 (no) 2001-02-05
CN1072963C (zh) 2001-10-17
UA44688C2 (uk) 2002-03-15
SA93130573B1 (ar) 2004-08-31
FI110843B (fi) 2003-04-15

Similar Documents

Publication Publication Date Title
RU94042386A (ru) Вакцина против гепатита, содержащая 3-0-дезацилированный монофосфорил-липида, применение антигена гепатита для получения препарата для лечения гепатита, способ лечения гепатита
RU94046232A (ru) Вакцинная композиция, применение композиции, способы лечения, способ приготовления композиции
ES2118963T3 (es) Vacunas combinadas, que contienen antigeno de superficie de la hepatitis b y otros antigenos.
HUT69803A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
ATE122654T1 (de) Behandlung von hiv-infizierungen und nützliche verbindungen dafür.
ES533111A0 (es) Un metodo de preparar una vacuna viva
AU2521792A (en) Chicken anaemia agent vaccine
DE3751772D1 (de) Impfstoff zur behandlung von hsv
BR9508629A (pt) Composto solvato e hidrato do mesmo processos para o tratamento ou profilaxia de uma infecção viral num ser humano e para a preparação do composto uso de um composto e formulação farmacêutica
DE3854857T2 (de) Verhütung und behandlung einer retrovirenkrankheit
UA42693C2 (ru) Лекарственное средство для лечения инфекции лентивирусом, препарат для лечения человека, который инфицирован лентивирусом
ES2096559T3 (es) Interferon gamma humano, procedimiento para la preparacion de dicho interferon gamma humano, y su uso.
RU94024812A (ru) Способ профилактики полиомиелита на крайнем севере
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.
RU94038588A (ru) Способ лечения вторичного иммунодефицита (вид)
RU98105627A (ru) Вакцины
Felfe et al. Trends in production of foot-and-mouth disease vaccine.
RU95108985A (ru) Фармацевтическая композиция "бактим" для профилактики вторичных иммунодефицитов и способ их профилактики
JPS53109912A (en) Condensed tannin, inactivation of microorganism-originated toxic substance, and attenuation of vaccines using condensed tannin
SU1797350A1 (ru) Способ обнаружения вируса иммунодефицита человека
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов